Glioma stem-like cells (GSCs) may be the initiating cells in
glioblastoma (GBM) and contribute to the resistance of these
tumors to conventional
therapies. Development of novel chemotherapeutic agents and treatment approaches against GBM, especially those specifically targeting GSCs are thus necessary. In the present study, we found that a novel
Janus kinase 2/
Signal Transducer and Activator of Transcription 3 (JAK2/STAT3) pathway inhibitor (
WP1193) significantly decreased the proliferation of established
glioma cell lines in vitro and inhibit the growth of
glioma in vivo. To test the efficacy of
WP1193 against GSCs, we then administrated
WP1193 to GSCs isolated and expanded from multiple human GBM
tumors. We revealed that
WP1193 suppressed phosphorylation of JAK2 and STAT3 with high potency and demonstrated a dose-dependent inhibition of proliferation and neurosphere formation of GSCs. These effects were at least due in part to G1 arrest associated with down-regulation of
cyclin D1 and up-regulation of p21( Cip1/Waf-1 ). Furthermore,
WP1193 exposure decreased expression of stem cell markers including CD133 and c-myc, and induced cell death in GSCs through apoptosis. Taken together, our data indicate that
WP1193 is a potent small molecule inhibitor of the JAK2/STAT3 pathway that shows promise as a therapeutic agent against GBM by targeting GSCs.